scholarly journals A study of serum levels of prostate specific antigen, prostate acid phosphatase in prostate cancer patients and its complications on liver

2021 ◽  
Vol 8 (2) ◽  
pp. 554
Author(s):  
Balakrishna S. V. ◽  
Veerabhadra Goud G. K. ◽  
Veluri Ganesh
Keyword(s):  
Prostate Cancer ◽  
Acid Phosphatase ◽  
Early Detection ◽  
Liver Function ◽  
Cancer Patients ◽  
Specific Antigen ◽  
Serum Levels ◽  
Liver Function Tests ◽  
Healthy Controls ◽  
Pathological Changes

Background: The prostate cancer (PC) is most leading disorders in human beings particularly in males. Prostate specific antigen (PSA) and prostate acid phosphatase (PAP) are tumor markers useful for early detection and diagnosis of PC. In prostate cancer patients more prone to liver and bone cancer metastasis because in these patients elevated levels of serum liver function tests (LFT) and these liver enzymes more specific for early detection of pathological changes in liver and bones.Methods: This is the case control study was carried out the association of serum levels of PSA/PAP inpatients with prostate cancer and healthy controls. Total 120 subjects included in this study in that 60 PC patients and 60 controls was included and blood was collected. The serum PSA levels are estimated by ELISA, PAP estimated by Kinetic method and LFT Was analyzed by commercial kits. Results: The present study evaluates the serum levels of LFT, PSA and PAP in patients with prostate cancer and compared with the healthy controls. The statistically significant difference between the PSA, PAP and LFT levels in patients with PC when compared to controls. The positive correlation in between PSA, PAP with LFT (p=0.001).Conclusions: This study suggesting that the serum PSA, PAP levels sensitive parameters for early detection of prostatic cancer and also for these patients’ frequent measurements of serum liver function tests, useful for early detection of significant pathological changes occurs in the liver and bone cancers metastasis from prostate.   

scholarly journals Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer

ISRN Oncology ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Michiko Takakura ◽  
Akira Yokomizo ◽  
Yoshinori Tanaka ◽  
Michimoto Kobayashi ◽  
Giman Jung ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Carbonic Anhydrase ◽  
Cancer Patients ◽  
Plasma Proteins ◽  
Specific Antigen ◽  
Healthy Controls ◽  
Gray Zone ◽  
Plasma Biomarker ◽  
Carbonic Anhydrase I ◽  
Discrimination Rate

Serum prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/mL is considered a diagnostic gray zone for detecting prostate cancer because biopsies reveal no evidence of cancer in 75% of these subjects. Our goal was to discover a new highly specific biomarker for prostate cancer by analyzing plasma proteins using a proteomic technique. Enriched plasma proteins from 25 prostate cancer patients and 15 healthy controls were analyzed using a label-free quantitative shotgun proteomics platform called 2DICAL (2-dimensional image converted analysis of liquid chromatography and mass spectrometry) and candidate biomarkers were searched. Among the 40,678 identified mass spectrum (MS) peaks, 117 peaks significantly differed between prostate cancer patients and healthy controls. Ten peaks matched carbonic anhydrase I (CAI) by tandem MS. Independent immunological assays revealed that plasma CAI levels in 54 prostate cancer patients were significantly higher than those in 60 healthy controls (, Mann-Whitney test). In the PSA gray-zone group, the discrimination rate of prostate cancer patients increased by considering plasma CAI levels. CAI can potentially serve as a valuable plasma biomarker and the combination of PSA and CAI may have great advantages for diagnosing prostate cancer in patients with gray-zone PSA level.

Insulin-like Growth Factor 1, Chromogranin A and Prostate Specific Antigen Serum Levels in Prostate Cancer Patients and Controls

2005 ◽  
Vol 48 (1) ◽  
pp. 34-39 ◽  
Author(s):  
Martin Marszalek ◽  
Johann Wachter ◽  
Anton Ponholzer ◽  
Thomas Leitha ◽  
Michael Rauchenwald ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Growth Factor ◽  
Cancer Patients ◽  
Prostate Specific Antigen ◽  
Chromogranin A ◽  
Specific Antigen ◽  
Serum Levels ◽  
Insulin Like Growth Factor

Clinical Utility of Prostatic Specific Antigen and Prostatic Acid Phosphatase Serum Levels in Monitoring Prostate Cancer

1988 ◽  
Vol 3 (1) ◽  
pp. 23-28 ◽  
Author(s):  
J. Morote ◽  
A. Ruibal ◽  
J. Palou ◽  
J. A. de Torres ◽  
A. Soler-Roselló
Keyword(s):  
Prostate Cancer ◽  
Acid Phosphatase ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Serum Levels ◽  
Response To Treatment ◽  
Prostatic Specific Antigen ◽  
Serum Samples ◽  
Better Than

We analysed 696 prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum samples by double antibody radioimmunoassay (RIA) I125 in the follow-up of 122 patients with prostate cancer under treatment. PSA levels were significantly correlated to response to treatment, whereas PAP results did not differentiate patients with partial or complete remission. Progression of the disease was detected in 95.2 and 85.4% of PSA and PAP samples, and increased to 99.9% using both simultaneously. On the whole, PSA was better than PAP in monitoring prostate cancer, and the efficacy was greater using both markers together.

scholarly journals Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Paula Kappler ◽  
Michael A. Morgan ◽  
Philipp Ivanyi ◽  
Stefan J. Brunotte ◽  
Arnold Ganser ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Cox Regression ◽  
Specific Antigen ◽  
Progression Free Survival ◽  
Serum Levels ◽  
Biologically Active ◽  
Free Form ◽  
Total Testosterone ◽  
The Impact

AbstractTo date, only few data concerning the biologically active, free form of testosterone (FT) are available in metastatic prostate cancer (mPC) and the impact of FT on disease, therapy and outcome is largely unknown. We retrospectively studied the effect of docetaxel on FT and total testosterone (TT) serum levels in 67 mPC patients monitored between April 2008 and November 2020. FT and TT levels were measured before and weekly during therapy. The primary endpoint was overall survival (OS). Secondary endpoints were prostate-specific antigen response and radiographic response (PSAR, RR), progression-free survival (PFS), FT/TT levels and safety. Median FT and TT serum levels were completely suppressed to below the detection limit during docetaxel treatment (FT: from 0.32 to < 0.18 pg/mL and TT: from 0.12 to < 0.05 ng/mL, respectively). Multivariate Cox regression analyses identified requirement of non-narcotics, PSAR, complete FT suppression and FT nadir values < 0.18 pg/mL as independent parameters for PFS. Prior androgen-receptor targeted therapy (ART), soft tissue metastasis and complete FT suppression were independent prognostic factors for OS. FT was not predictive for treatment outcome in mPC patients with a history of ART.

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter

Urology ◽  
2002 ◽  
Vol 60 (4) ◽  
pp. 31-35 ◽  
Author(s):  
Wolfgang Horninger ◽  
Carol D Cheli ◽  
Richard J Babaian ◽  
Herbert A Fritsche ◽  
Herbert Lepor ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Early Detection ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Serum Prostate Specific Antigen
Sign in / Sign up

Export Citation Format

Share Document